+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Decitabine"

Precision Cancer Therapies, Volume 1. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Edition No. 1 - Product Thumbnail Image

Precision Cancer Therapies, Volume 1. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Edition No. 1

  • Book
  • May 2023
  • 512 Pages
Loading Indicator

Decitabine is an oncology drug used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It is a DNA methyltransferase inhibitor, meaning it works by blocking the action of an enzyme that adds methyl groups to DNA, which can lead to gene silencing. Decitabine is administered intravenously and is approved for use in adults with MDS and AML. It is also being studied for use in other types of cancer. Decitabine is a relatively new drug, having been approved by the US Food and Drug Administration in 2006. It is used as a first-line treatment for MDS and as a second-line treatment for AML. It is generally well-tolerated, with the most common side effects being nausea, vomiting, and fatigue. The decitabine market is growing as more patients are being diagnosed with MDS and AML. The market is expected to continue to grow as new treatments are developed and more patients are treated with decitabine. Some companies in the decitabine market include AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer. Show Less Read more